Annovis Bio, Inc. — Q1 2021 Form 10-Q
Business context and period: Clinical-stage biotechnology company developing ANVS401, an oral candidate targeting neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, and Alzheimer’s disease in Down syndrome. This unaudited report covers the three months ended March 31, 2021, compared with Q1 2020.
Key financial results
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $2.390 million | $66,446 |
| General and administrative expense | $839,627 | $516,716 |
| Total operating expenses / operating loss | $3.229 million | $583,162 |
| Net loss | $3.200 million | $441,590 |
| Basic and diluted loss per share | $0.46 | $0.10 |
| Net cash used in operating activities | $2.475 million | $970,405 |
At March 31, 2021, cash and cash equivalents were $5.603 million, down from $8.075 million at December 31, 2020. Current assets were $5.965 million and current liabilities were $1.597 million, yielding working capital of approximately $4.368 million. The filing reports no outstanding debt; the prior convertible notes converted to common stock in 2020. No revenue-based margin is meaningful at this development stage.
Material changes and operating developments
- R&D expense rose by approximately $2.323 million year over year, primarily due to the ongoing AD/PD trial, clinical-material manufacturing, and personnel costs. Management attributed elevated quarterly trial costs partly to milestones achieved during the period.
- G&A expense increased approximately $323,000, principally because of higher accrued incentive compensation.
- Operating cash use increased approximately $1.505 million year over year, mainly reflecting the AD/PD trial. Q1 2021 financing cash flow was only $3,017 from option exercises; Q1 2020 included IPO proceeds.
- Common shares outstanding were 6,947,120 at March 31, 2021. The company also reported 1,107,598 outstanding options and 5,000 remaining underwriter warrants.
Outlook, risks, and contingencies
Management believed available cash would fund operations and capital requirements for at least 12 months, including completion of the Phase 2a AD and PD trials, which it expected to complete in mid-2021, and planning for a Phase 3 study. The company said Phase 3 trials would require additional capital; it had no committed external funding, and financing may not be available on acceptable terms.
The company was conducting two Phase 2a studies: an ADCS study planned for 24 early-AD patients, with 14 having completed treatment before COVID-19-related enrollment suspension, and an AD/PD study planned for 14 AD and 54 PD patients. Trial sites had reopened and recruitment and treatment had resumed. Management expected timely completion but noted that the pandemic could still affect trial progress.
The company has never been profitable or generated positive operating cash flow and expects further losses. Other disclosed exposures include a $46,000 minimum annual license commitment, potential milestone and royalty payments under its license, and maximum aggregate executive severance payments of approximately $720,000. No material litigation was pending. The NIH toxicology grant had $7,414 remaining at quarter-end.
Investor verification priorities
- Verify trial enrollment, completion timing, and any subsequent clinical or regulatory updates for the ADCS and AD/PD studies.
- Assess whether the stated 12-month cash runway remains adequate given the $2.475 million quarterly operating cash use and planned development spending.
- Monitor the timing, cost, and funding plan for Phase 3; management stated additional capital would be needed.
- Review subsequent changes in R&D spending, manufacturing commitments, and licensing or milestone obligations.
- Confirm the impact of COVID-19 or other operational delays on trial timelines and cash requirements.